Learn

Join a powerhouse faculty as we unpack the implications of expanded SGLT2 inhibitor eligibility - a genuine turning point in CKD that opens the door for earlier intervention in a wider group of patients. This masterclass will clarify what has changed, who is now eligible, and how to put the new thresholds into routine practice. Faculty will use real cases and pragmatic workflows that can be applied immediately in day-to-day chronic disease care.

Details

Disclaimer: Please note, once you click 'Register now' you will be leaving the AMA’s CPD Home website and entering a third-party education provider’s website. If you choose to register for this learning, you will need to provide some of your personal information directly to the third-party education provider. If you have any queries about how third-party education providers use, disclose or store your personal information you should consult their privacy policy.